Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 11/2001

01-01-2001 | ORIGINAL ARTICLE

Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon α in the treatment of metastatic renal cell carcinoma: a pilot study

Authors: Jörg Westermann, Gernot Reich, Joachim Kopp, Ulrike Haus, Bernd Dörken, Antonio Pezzutto

Published in: Cancer Immunology, Immunotherapy | Issue 11/2001

Login to get access
Metadata
Title
Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon α in the treatment of metastatic renal cell carcinoma: a pilot study
Authors
Jörg Westermann
Gernot Reich
Joachim Kopp
Ulrike Haus
Bernd Dörken
Antonio Pezzutto
Publication date
01-01-2001
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 11/2001
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s002620000159

Other articles of this Issue 11/2001

Cancer Immunology, Immunotherapy 11/2001 Go to the issue

ORIGINAL ARTICLE

Characterization of CD8+ cytotoxic T lymphocyte/tumor cell interactions reflecting recognition of an endogenously expressed murine wild-type p53 determinant

ORIGINAL ARTICLE

Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient

ORIGINAL ARTICLE

Tumour-induced suppression of immune response and its correction

ORIGINAL ARTICLE

Induction of cytolytic T lymphocytes by immunization of mice with an adenovirus containing a mouse homolog of the human MAGE-A genes

ORIGINAL ARTICLE

The murine CC chemokine, 6C-kine, inhibits tumor growth and angiogenesis in a human lung cancer SCID mouse model
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits